Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in December

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,840,000 shares, an increase of 8.2% from the December 15th total of 3,550,000 shares. Based on an average daily trading volume, of 463,300 shares, the short-interest ratio is presently 8.3 days.

Institutional Trading of Aldeyra Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. King Wealth Management Group boosted its position in Aldeyra Therapeutics by 24.5% during the 3rd quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 2,700 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Aldeyra Therapeutics by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 2,729 shares during the period. SG Americas Securities LLC grew its position in shares of Aldeyra Therapeutics by 14.4% during the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 2,822 shares during the last quarter. US Bancorp DE bought a new position in shares of Aldeyra Therapeutics during the third quarter worth about $30,000. Finally, Captrust Financial Advisors increased its holdings in shares of Aldeyra Therapeutics by 89.3% in the 3rd quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 9,087 shares during the period. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Stock Up 1.3 %

Shares of ALDX opened at $4.84 on Tuesday. Aldeyra Therapeutics has a 12-month low of $2.71 and a 12-month high of $6.55. The business’s fifty day moving average price is $4.92 and its 200 day moving average price is $4.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). Research analysts anticipate that Aldeyra Therapeutics will post -0.92 earnings per share for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.